Fig. 5.

Velade pretreatment enhances cisplatin-induced apoptosis. MPM cells were treated with vehicle (DMSO), indicated doses of Vel-cade (indicated as Bortezomib) or cisplatin for 48 h. For combination study, cells were pretreated with Velcade for 24 h followed by addition of cisplatin for further 24 h. Cell lysates were utilized for western blot analyses with indicated antibodies in a while apoptosis-associated cellular morphologic changes in the treated cells were documented by phase-contrast microscopy in b. In c, apoptosis levels were quantitated by caspase-3 activation assay as described in “Methods”. Histogram columns, means of two independent experiments; bars SE